Board of Directors

Nominated by the Trustees of St Vincent's Hospital

Dr Schubert is Chairman of the Garvan Institute of Medical Research and a director of the Garvan Research Foundation Board. He has held positions as Chairman of the Great Barrier Reef Foundation, Chairman of the Commonwealth Bank of Australia, non-executive director of BHP Billiton Limited, BHP Billiton Plc, and Qantas Airways Limited, Chief Executive Officer of Pioneer International Limited, Chairman of WorleyParsons Limited and G2 Therapies Ltd, Chairman and MD of Esso Australia Ltd, and non-executive director of Hanson Plc.

Nominated by the Trustees of St Vincent’s Hospital

The Hon Dr Bennett is a former Judge of the Federal Court of Australia. She is presently Chancellor of Bond University, Arbitrator with the Court of Arbitration for Sport, Chair of the Australian Nuclear Science and Technology Organisation (ANSTO), Chair of Gardior Pty Ltd, the Trustee of The Infrastructure Fund (TIF). Dr Bennett has extensive knowledge and experience in intellectual property arising from her position as a Judge, as a senior counsel specialising in Intellectual Property, as President of the Copyright Tribunal and as former Chair of the Advisory Group of Judges to the World Intellectual Property Organisation (WIPO).

Nominated by the Sisters of Charity

Associate Professor Philip Cunningham OAM is the Chief Operating Officer at the St Vincent's Centre for Applied Medical Research and Chief Scientist at the NSW State Reference Laboratory for HIV at St Vincent's Hospital. He is Co-Chair of the National HIV Testing Policy Expert Reference Group, a visiting senior research fellow at the Kirby Institute, UNSW Sydney, and former Vice President of the Australasian Society of HIV Medicine (ASHM).

Nominated by the Garvan Research Foundation

Mr Johns is the independent Chairman of the ASX listed Goodman Group and a director of the European Australia Business Council. He is a former chairman and non-executive director of three ASX listed entities - Brambles Limited, Leighton Holdings Limited and Spark Infrastructure Group - and a former Finance Director and, upon his retirement from executive duties, a non-executive director of the Westfield Group. He has a Bachelor of Economics degree from the University of Sydney and is a Fellow of the Institute of Chartered Accountants in Australia and the Australian Institute of Company Directors.

Nominated by the Trustees of St Vincent's Hospital

Dr Kelly is a Founding Partner of OneVentures and serves on the investment committee of OneVentures' three main Funds, chairing the Healthcare Fund III Investment Committee, and leads the healthcare and biotechnology practice across the firm. He is currently Chair on the boards of OneVentures investee companies Vaxxas and Hatchtech and is non-executive director of BiVACOR, Clinical Genomics and Prota Therapeutics. Dr Kelly is an Australian physician and serial biotechnology entrepreneur with over 30 years' experience in developing and commercialising biomedical innovations in the US, Europe, UK and Australia. While in the UK and US he led early-stage and mid-stage companies, public and private, with a record of achievement in transforming ideas, technologies and products into sustainable successful businesses and delivering strong returns for shareholders and investors as a founder and CEO.

Nominated by the Garvan Board

Executive Director of the Garvan Institute of Medical Research, Professor Benjamin Kile is an internationally recognised medical researcher who has made contributions to the understanding of cancer, stem cells and inflammatory disease. His work has shed light on the mechanisms of programmed cell death, informing the development of the BH3 mimetics, a new class of cancer drugs approved by the FDA in 2016. Professor Kile has a distinguished research leadership background, having occupied senior roles at the Walter and Eliza Hall Institute, Monash University, and the University of Adelaide. He made foundational contributions to the establishment of the National Drug Discovery Centre, the South Australian immunoGENomics Cancer Institute, and the Bragg Comprehensive Cancer Centre.

Nominated by the NSW Minister for Health

Dr Nugent is the Chairman of Ausgrid and The Order of Australia Association Foundation Limited; Senior Independent Director of TPG Telecom; and a Non-Executive Director of Insurance Australia Group, the Australia Olympic Foundation and NPGA Foundation. She was previously Chairman of the National Disability Insurance Agency, the National Portrait Gallery of Australia, Veda Group, Australian Rail Track Corporation, Funds SA, Swiss Re (Australia) and Sydney Airport and a Non-Executive Director of Macquarie Group, among others. She is a Companion of the Order of Australia, a recipient of the Australian Government Centenary Medal and was awarded the Order of Merit by the Australian Olympic Committee. She has also been awarded Honorary Doctorates by the University of Queensland and Bond University.

Nominated by UNSW Sydney

Professor Perkovic is the Dean of the Faculty of Medicine at UNSW Sydney, an expert clinician in nephrology, and a Non-Executive Director of St Vincents Health Australia, as well as several independent Medical Research Institutes. He has previously been the Executive Director of The George Institute, President of the Association of Australian Medical Research Institutes and on the Board of the Australian Clinical Trials Alliance. He is a fellow of the Royal Australasian College of Physicians, and of the Australian Academy of Health and Medical Sciences.

Nominated by the Federal Minister for Health

Professor Reddel is a medical oncologist, molecular geneticist and an internationally renowned expert on cancer cell immortalisation. He is Executive Director of Children’s Medical Research Institute (CMRI), Westmead, the Sir Lorimer Dods Professor of the University of Sydney, and a Fellow of the Australian Academy of Science, the Australian Academy of Health and Medical Sciences, the Royal Society of NSW, and the Royal Australasian College of Physicians.

Nominated by the Federal Minister for Health

Dr Scrimshaw is the Garvan Research Foundation Board Chairman and a Non-Executive Director of the Garvan Institute of Medical Research. He is currently Executive Chairman of Peak Rare Earths Ltd, Deputy Chairman of Ignition Wealth P/L, Non-Executive Chairman of ARI P/L and Scrimshaw Nominees P/L and also of Australian Philanthropic Fund, the Scrimshaw Foundation. Previously, he has held senior executive positions at Fortescue Metals Group Ltd (FMG), Commonwealth Bank, Optus and IBM. He was also Non-Executive Chairman at Sirius Minerals plc, and Executive Director at FMG, and Non-Executive Director of Commonwealth Properties Ltd, EDS Australia, Mobilesoft, Telecom New Zealand Australia P/L, and Athletics Australia.

Nominated by UNSW Sydney

Ms Segal is the chairman of AICC (NSW), General Sir John Monash Foundation and the Independent Parliamentary Expenses Authority (IPEA). She is President of the Executive Council of Australian Jewry (ECAJ), a director of the Grattan Institute and of Rabobank Australia Limited. She is a member of the International Board of the Weizmann Institute of Science. She has been a senior regulator, lawyer and a director of other listed and government organisations and was previously the Deputy Chancellor of UNSW Sydney.

Nominated by the NSW Minister for Health

Professor Trent is Head of the Department of Medical Genomics at the Royal Prince Alfred Hospital and Director for the Institute of Precision Medicine & Bioinformatics at the Sydney Local Health District. He is the President of the School Council for the Sydney Boys High School, and past Secretary of the Sydney Girls High School Foundation. He is a fellow of the Royal Australasian College of Physicians, the Royal College of Pathologists of Australasia, and of the Australian Academy of Technology and Engineering.